Add Yahoo as a preferred source to see more of our stories on Google. Spinogenix's first-in-class ALS treatment Spinogenix is progressing its lead candidate, SPG302, to a registrational trial ...

Add Yahoo as a preferred source to see more of our stories on Google. Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com (MAXIMUM ...

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people ...

Experimental therapy RT1999 will soon be tested in the UK EXPERTS-ALS platform trial designed to rapidly screen potential ALS treatments.

As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing ...

"Watching my mom die of ALS was one of the most awful things I’ve gone through. I don’t want my children to see me suffer ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...

Clinical efficacy results (secondary endpoints) and safety results (primary endpoints) expected December 2023 Biogen collaboration biomarker results expected Q1 2024 Primary biomarker endpoints to be ...

Yentli Soto Albrecht has a rare genetic form of ALS and is working on research at Penn that could one day prove life-saving.

NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for ...

The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for its advancement to the HEALEY-ALS trial. The company’s lead drug in ...